Keyword: Eli Lilly

Roche has the pipeline it needs for growth, its chairman said, but the company could add on with small- or medium-sized M&A.

A close look at SEC documents describing Lilly's bid for Loxo indicates more interest in targeted oncology than the deal's genesis might indicate, analysts say.

Lilly's Lartruvo has been a key launch for its oncology business, but thanks to a phase 3 fail, it plans to stop promoting the drug.

NICE initially told Eli Lilly that its breast cancer drug Verzenio wasn't cost-effective. So Lilly dished up a price break—and it worked.

Patients using copay coupons were more likely to stay on their drugs longer, but the vouchers didn't help with outcomes, a new study found.

It wasn't just deals folks were buzzing about in meeting rooms, restaurants and hotel lobbies, as our top FierceBiotech and FiercePharma stories show.

Eli Lilly says it's cutting 250 positions in France through a "voluntary exit plan" as it "modernizes" a Fegersheim plant.

England's National Institute for Health and Care Excellence says available clinical data aren't enough to demonstrate Aimovig's cost-effectiveness.

Here are some other manufacturing news stories we're following.